Artificial intelligence (AI) and real-world evidence (RWE) are playing a growing role across oncology development—from patient stratification and trial design to post-approval monitoring. As adoption accelerates, regulators are setting clearer expectations to ensure these tools are applied with transparency, rigor, and accountability. ...
Antibody–drug conjugates (ADCs) are rapidly reshaping the oncology treatment landscape. By combining the targeting precision of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, ADCs offer the promise of improved efficacy with more controlled toxicity. This potential has fueled...
Achieving First Patient In (FPI) in a radiopharmaceutical (RP) trial demands a highly coordinated approach that balances regulatory complexity, specialized site requirements, and intricate logistics. This guide outlines the most common barriers to FPI and provides practical strategies to help...
As the pace of innovation in oncology accelerates, artificial intelligence (AI) and real-world evidence (RWE) are reshaping how researchers understand disease, design studies, and deliver care. These technologies are bridging science, data, and clinical insight in ways that were once...